Psyence BioMed (NASDAQ: PBM) provided a comprehensive corporate update highlighting significant progress across multiple fronts. The company reported a strong cash position of $11.4 million with no outstanding debt and successfully regained Nasdaq compliance following a 1-for-7.97 reverse stock split.
Key developments include protocol amendments to expand patient eligibility in clinical trials, activation of three ...
Psyence BioMed (Nasdaq: PBM) announced that its strategic partner, PsyLabs, has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract meeting food-grade consumption safety standards. This achievement follows PBM’s strategic equity investments in PsyLabs during 2024 and 2025.
The breakthrough represents a significant milestone in producing high-quality psychedelic APIs, with PsyLabs’ extract passing third-party laboratory verification. ...